Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Shares Shorted: Short Interest Down 59.6% in October

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw a significant decline in short interest in October. As of October 15th, there was short interest totaling 33,053 shares, a decline of 59.6% from the September 30th total of 81,750 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 679,428 shares, the short-interest ratio is currently 0.0 days.

Analysts Set New Price Targets

Several research firms have weighed in on CHGCY. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Price Performance

Shares of OTCMKTS CHGCY opened at $20.98 on Thursday. The company has a market cap of $69.05 billion, a P/E ratio of 22.80 and a beta of 0.60. Chugai Pharmaceutical has a 1 year low of $18.33 and a 1 year high of $34.84. The firm has a 50-day simple moving average of $20.76 and a two-hundred day simple moving average of $24.58.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its earnings results on Tuesday, October 27th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $2.54 billion during the quarter, compared to analyst estimates of $2.29 billion. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. As a group, equities research analysts expect that Chugai Pharmaceutical will post 1.00 EPS for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.